207 related articles for article (PubMed ID: 32318342)
41. Genomics and Epigenetics of Malignant Mesothelioma.
Sage AP; Martinez VD; Minatel BC; Pewarchuk ME; Marshall EA; MacAulay GM; Hubaux R; Pearson DD; Goodarzi AA; Dellaire G; Lam WL
High Throughput; 2018 Jul; 7(3):. PubMed ID: 30060501
[TBL] [Abstract][Full Text] [Related]
42. Targeting the epigenome in malignant pleural mesothelioma.
McLoughlin KC; Kaufman AS; Schrump DS
Transl Lung Cancer Res; 2017 Jun; 6(3):350-365. PubMed ID: 28713680
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy.
Tomasetti M; Gaetani S; Monaco F; Neuzil J; Santarelli L
Front Oncol; 2019; 9():1293. PubMed ID: 31850200
[TBL] [Abstract][Full Text] [Related]
44. Editorial: Epigenetic Modifications in Mesothelioma.
Cheng YY; Yuen ML; Jin H
Front Oncol; 2021; 11():650136. PubMed ID: 33614517
[No Abstract] [Full Text] [Related]
45. Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?
Røe OD
J Thorac Dis; 2018 Jun; 10(Suppl 17):S1956-S1961. PubMed ID: 30023090
[No Abstract] [Full Text] [Related]
46. Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources?
Cornelissen R; Aerts JGJV
J Thorac Dis; 2018 Apr; 10(Suppl 9):S1084-S1087. PubMed ID: 29850188
[No Abstract] [Full Text] [Related]
47. Epigenetic biomarkers in cancer.
Egger G
ESMO Open; 2018; 3(5):e000416. PubMed ID: 30116593
[No Abstract] [Full Text] [Related]
48. The Molecular Basis of Malignant Pleural Mesothelioma.
Wadowski B; De Rienzo A; Bueno R
Thorac Surg Clin; 2020 Nov; 30(4):383-393. PubMed ID: 33012428
[TBL] [Abstract][Full Text] [Related]
49. The Use of Immunohistochemistry, Fluorescence
Rozitis E; Johnson B; Cheng YY; Lee K
Front Oncol; 2020; 10():1742. PubMed ID: 33014860
[TBL] [Abstract][Full Text] [Related]
50. Malignant pleural mesothelioma: recent developments.
Sinn K; Mosleh B; Hoda MA
Curr Opin Oncol; 2021 Jan; 33(1):80-86. PubMed ID: 33186182
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment.
Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T
Front Oncol; 2020; 10():554570. PubMed ID: 33381446
[TBL] [Abstract][Full Text] [Related]
52. The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.
Lettieri S; Bortolotto C; Agustoni F; Lococo F; Lancia A; Comoli P; Corsico AG; Stella GM
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33802313
[TBL] [Abstract][Full Text] [Related]
53. Mesothelioma Biomarkers: Discovery in Search of Validation.
Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
Thorac Surg Clin; 2020 Nov; 30(4):395-423. PubMed ID: 33012429
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos.
Di Mauro G; Frontini F; Torreggiani E; Iaquinta MR; Caselli A; Mazziotta C; Esposito V; Mazzoni E; Libener R; Grosso F; Maconi A; Martini F; Bononi I; Tognon M
Sci Rep; 2023 Apr; 13(1):6501. PubMed ID: 37081052
[TBL] [Abstract][Full Text] [Related]
55. Next Generation Sequencing for miRNA Detection on the Exhaled Breath Condensate: A Pilot Study.
Cherchi R; Cusano R; Orrù S; Ferrari PA; Massidda M; Fotia G; De Matteis S; Cocco P
Epigenet Insights; 2023; 16():25168657231160985. PubMed ID: 37025420
[TBL] [Abstract][Full Text] [Related]
56. Serum diagnostic markers for malignant pleural mesothelioma: a narrative review.
Wang JJ; Yan L
Transl Cancer Res; 2022 Dec; 11(12):4434-4440. PubMed ID: 36644178
[TBL] [Abstract][Full Text] [Related]
57. Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study.
Casalone E; Birolo G; Pardini B; Allione A; Russo A; Catalano C; Mencoboni M; Ferrante D; Magnani C; Sculco M; Dianzani I; Grosso F; Mirabelli D; Filiberti RA; Rena O; Sacerdote C; Rodriguez-Barranco M; Smith-Byrne K; Panico S; Agnoli C; Johnson T; Kaaks R; Tumino R; Huerta JM; Riboli E; Heath AK; Trobajo-Sanmartín C; Schulze MB; Saieva C; Amiano P; Agudo A; Weiderpass E; Vineis P; Matullo G
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612122
[TBL] [Abstract][Full Text] [Related]
58. Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma.
Ferrari L; Iodice S; Cantone L; Dallari B; Dioni L; Bordini L; Palleschi A; Mensi C; Pesatori AC
Med Lav; 2022 Dec; 113(6):e2022052. PubMed ID: 36475505
[TBL] [Abstract][Full Text] [Related]
59. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms.
Cersosimo F; Barbarino M; Lonardi S; Vermi W; Giordano A; Bellan C; Giurisato E
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830817
[TBL] [Abstract][Full Text] [Related]
60. Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
Yeo D; Castelletti L; van Zandwijk N; Rasko JEJ
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
